Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696031 | 0.87 | IDO1 (0.50) | CA2IDO1AGXTDAOKDM4E | |
| SCHEMBL2335579 | 0.87 | IDO1 (0.50) | CA2IDO1AGXTDAOKDM4E | |
| SCHEMBL2338933 | 0.83 | CA2 (0.45) | CA2IDO1AGXTMPOSLC6A4 | |
| SCHEMBL31617901 | 0.82 | MPO (0.48) | CA2IDO1AGXTDAOMPO | |
| SCHEMBL7700904 | 0.82 | IDO1 (0.58) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL29745090 | 0.81 | MPO (0.54) | CA2IDO1AGXTDAOKDM4E | |
| SCHEMBL6193002 | 0.81 | MPO (0.54) | CA2IDO1AGXTDAOKDM4E | |
| SCHEMBL3637969 | 0.80 | CA2 (0.46) | CA2IDO1AGXTMPOSLC6A4 | |
| SCHEMBL30817945 | 0.80 | CA2 (0.46) | CA2IDO1AGXTMPOSLC6A4 | |
| SCHEMBL27565478 | 0.80 | CA2 (0.42) | CA2KDM4ESMN1; SMN2MPOSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105646137-B | The method of one kind 1 (1 chloromethyl vinyl base) 2,4 difluorobenzenes of synthesis | 宁波新凯生物科技有限公司 | 2018-04-13 | — | — | CN | claimed |
| CN-105622413-B | The synthetic method of 2 [2 (2,4 difluorophenyl) pi-allyl] 1,3 diethyl malonates | 宁波新凯生物科技有限公司 | 2017-11-24 | — | — | CN | claimed |
| US-20180201592-A1 | 2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2018-07-19 | — | — | US | disclosed |
| CN-105646137-B | The method of one kind 1 (1 chloromethyl vinyl base) 2,4 difluorobenzenes of synthesis | 宁波新凯生物科技有限公司 | 2018-04-13 | — | — | CN | disclosed |
| CN-105732310-B | The synthetic method of 2 [base of 2 (2,4 difluorophenyl) 2 propylene 1] 1,3 propane diols | 宁波新凯生物科技有限公司 | 2018-01-23 | — | — | CN | disclosed |
| CN-105753693-B | The synthetic method of 2 methylpropanoic acids [base of 4 amylene of (2S) 4 (2,4 difluorophenyl) 2 methylol 1] ester | 宁波新凯生物科技有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-105622413-B | The synthetic method of 2 [2 (2,4 difluorophenyl) pi-allyl] 1,3 diethyl malonates | 宁波新凯生物科技有限公司 | 2017-11-24 | — | — | CN | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| CN-102056907-B | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2014-12-31 | — | — | CN | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | CA2 129/4885IDO1 4331/4885AGXT 4810/4885 |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | S1PR3, S1PR2, S1PR1 | CA2 1077/4885IDO1 311/4885AGXT 3011/4885 |
| US-20180201592-A1 | 2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS | NAT1, DPM1, IL4I1 | CA2 239/4885IDO1 12/4885AGXT 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.